LH活性药物联合FSH促排在Poseidon 1组、2组患者的疗效分析  

The efficacy of the administeration of LH analogues in combination with FSH in Poseidon group 1 and group 2 patients

作　　者：谢重驹 刘寒艳[1] 刘见桥[1] XIE Zhong-ju;LIU Han-yan;LIU Jian-qiao(Department of Obstetrics and Gynecology,Center for Reproductive Medicine,Key Laboratory for Major Obstetric Diseases of Guangdong Province,Key Laboratory for Reproductive Medicine of Guangdong Province,The Third Affiliated Hospital of Guangzhou Medical University,Guangzhou 510150,China)

机构地区：[1]广州医科大学附属第三医院妇产科,生殖医学中心,广东省产科重大疾病重点实验室,广东省生殖医学重点实验室,广州510150

出　　处：《中国处方药》2022年第2期13-16,共4页Journal of China Prescription Drug

摘　　要：目的探讨使用FSH联合LH活性药物促排在Poseidon 1组、2组低预后患者中的有效性。方法回顾分析2014年1月~2019年12月在广州医科大学附属第三医院进行IVF/ICSI助孕Poseidon 1组、2组低预后患者的临床资料。将患者分为两组:FSH组(单纯使用FSH促排,共1679例1740周期)、FSH+LH组(FSH联合LH活性药物促排,共471例478周期),比较两组间的基础指标及临床结局指标,其中卵泡-卵母细胞转化指数(Follicle-To-Oocyte Index,FOI)为主要的结局指标。结果FSH+LH组与FSH组的卵巢储备基线差异无统计学意义(P>0.05)。FSH组的FOI较高,卵泡输出率(Follicular Output Rate,FORT)、获卵数、MII卵率、受精率、临床妊娠率、胚胎种植率等结局指标与FSH+LH组无统计学差异(P>0.05)。结论黄体期长方案常规联合LH活性药物促排,并不能改善非预期卵巢反应不良患者的结局,且增加患者经济成本,不推荐常规使用。Objective To investigate the efficacy of LH analogues combined with FSH in ovarian stimulation cycles of patients with low prognosis in Poseidon group 1 and group 2.Methods An observational retrospective cohort study was performed in Poseidon group 1 and group 2 low prognosis patients who received IVF/ICSI treatments in the Third Affiliated Hospital of Guangzhou Medical University from January 2014 to December 2019.The patients were divided into two groups according to whether LH analogues were administered:FSH group(1679 cases with 1740 cycles of FSH stimulation alone),FSH+LH group(471 cases with 478 cycles of LH analogues combined with FSH stimulation).The base-line data and the clinical outcome indexes were compared between two group.Follicle-To-Oocyte Index(FOI)was the main outcome index.Results No statistical difference in baseline of ovarian reserve was detected between group FSH+LH and group FSH(P>0.05).Group FSH was of higher FOI.There were no statistic differences in outcome indexes such as Follicular Output Rate(FORT),retrieval oocytes,MII oocytes rates,fertilization rates,clinical pregnancy rates and embryo implantation rates between two group(P>0.05).Conclusion The administration of FSH in combination with LH analogues can not improve clinical outcomes of patients with unexpected inadequate ovarian response in luteal-phase GnRH agonist long protocol,besides,there is higher cost during ovarian stimulation.It is not routinely recommended.

关 键 词：POSEIDON 促黄体生成素 超促排卵 辅助生殖技术 

分 类 号：R969[医药卫生—药理学]